IRD

#3307
Opus Genetics, Inc. - Common Stock
3.6 9 USD
-0.04%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
3.69
3.69
Jahresspanne
2.82
5.81
Tagesänderung
-4.16%
Monatliche Änderung
-4.16%
6 month change
-9.56%
Jahresänderung
-0.81%
Vorheriger Schlusskurs
3.8 5
Open
3.6 9
Tief
3.6 9
Hoch
3.6 9
Volumen
59
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Opus Genetics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Opus Genetics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Opus Genetics, Inc. quarterly report, Q1 FY2026
10-Q

Opus Genetics, Inc. current report, 02 January 2018

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on January 4, 2018, covering events occurring on January 2, 2018. The filing discloses the appointment of a new President and Chief Financial Officer and the departure of the previous CFO.

Key Financial Metrics

The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms:

  • Base Salary: $350,000 annually for the new President and CFO.
  • Target Bonus: 40% of base salary (subject to performance objectives).
  • Equity Grant: 250,000 stock options granted on January 2, 2018.
  • Vesting Schedule: 25% on the first anniversary; remaining 75% in 36 equal monthly installments.

Material Changes

The primary material change is a leadership transition in the finance function:

  • Appointment: Douglas J. Swirsky was appointed President and Chief Financial Officer effective January 2, 2018.
  • Departure: Tae Heum "Ted" Jeong resigned as Senior Vice President of Finance, Chief Financial Officer, and Secretary (announced December 2017).
  • Role Transfer: Mr. Swirsky assumes the roles of Principal Financial Officer and Principal Accounting Officer.

Outlook, Risks, and Contingencies

The filing details significant severance contingencies in the new Employment Agreement:

  • Termination without Cause/Good Reason: Entitles the executive to accrued obligations, a lump sum equal to one year's base salary, pro-rata target bonus, 12 months of COBRA, and accelerated vesting of options that would have vested in the following 12 months.
  • Change of Control: If termination occurs within two years of a Change of Control, the executive receives accrued obligations, 18 months of base salary, target bonus for the current and prior fiscal years, 18 months of COBRA, and full accelerated vesting of all equity awards.
  • Restrictive Covenants: Includes a 12-month non-solicitation clause for executives, employees, customers, and clients post-termination.

Investor Verification Checklist

  • Verify the exact vesting terms and exercise price of the 250,000 stock options granted to Mr. Swirsky.
  • Confirm the specific performance objectives required to achieve the 40% target bonus.
  • Review the full text of the Employment Agreement (Exhibit 10.1) for definitions of "Cause," "Good Reason," and "Change of Control."
  • Assess the impact of the leadership change on the company's ongoing financial reporting and strategic direction.